http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CO-6241160-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2eecae1b04e7c0235060c68623ea71ef |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-75 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-70585 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57415 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57419 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57434 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2884 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6897 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57438 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-1063 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57449 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B82Y5-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-1072 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-1051 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5082 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6849 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-574 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-30 |
| filingDate | 2009-11-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7eab3448f09bf34d86b6e659216d3d01 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_132930d6556ebb382637ed2c04823c0d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b284251d15ad641222cb6378c0ed882b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a8dd8a7ee52eeb3c118d0c2040b78f97 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cc306ad56afa2e9e626f73896f3edfa2 |
| publicationDate | 2011-01-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CO-6241160-A2 |
| titleOfInvention | ANTI-CD44 CHEMICAL AND HUMANIZED ANTIBODIES THAT MEDIATION THE CYCLOTOXICITY OF CANCER CELLS |
| abstract | CD44, a single chain hyaluronic acid (HA) binding glycoprotein, is expressed in a variety of normal tissues, all hematopoietic cells and various cancer tissues. A CD44 monoclonal antibody against the H460-16-2 hybridoma, deposited with ATCC as PTA-4621, was previously shown to be a cancerous disease modifying antibody (CDMAB), which prevents tumor growth and reduces tumor burden in cancer models including cancer of prostate and breast by cytotoxicity. Variable regions of the monoclonal stentibody were also isolated and sequenced to generate a chimeric antibody that has improved anti-cancer activity with respect to the monoclonal antibody. Now, humanized antibodies are generated that have similar activity of binding to CD44 as the monoclonal antibody PTA-4621 of origin. Monoclonal, chimeric and humanized antibodies can be combined with toxins, enzymes, radioactive compounds, cytokines, interferons, target portions or hematogenous cells to treat cancer. These antibodies are also used in binding assays to determine CD44 expression in cells. for the reduction of a human breast prostate tumor in a mammal, where the human breast or prostate tumor expresses at least one epitope of an antigen that specifically binds to the isolated monoclonal antibody produced by the inhibited cell line deposited with the ATCC as an accession number PTA -4621 or a CDMAB thereof whose CDMAB is characterized by the ability to competitively inhibit the release of the isolated monoclonal antibody to its antigen objective, characterized in that it comprises administering the monoclonal antibody or CDMAB thereof in an effective amount to result in a reduction in tumor burden of pro Mammalian Stata or Breast. 2. Method according to claim 1, characterized in that the human monoclonal antibody is conjugated to a cytotoxic portion. 3. Method according to claim 2, characterized in that the cytotoxic portion is an isotopeporadioactive. 4. - Method according to claim 1, characterized in that the isolated monoclonal antibody oCDMAB thereof activates the complement. 5. Method according to claim 1, characterized in that the isolated monoclonal antibody oCDMAB of the same mediates antibody-dependent cellular cytotoxicity. |
| priorityDate | 2007-05-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
| Predicate | Subject |
|---|---|
| isDiscussedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID23663392 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID450770914 |
Total number of triples: 44.